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Purpose: There is no consensus across guidelines on a diagnostic algorithm for upper urinary 
tract (UUT) evaluation following presentation with haematuria. Our aim is to compare the 
diagnostic accuracy of Ultrasound (USS) compared to CT-scan for UUT malignancies and also 
determine the considerations important for a risk-based diagnostic protocol for haematuria. 
Methods: We reviewed our ‘haematuria clinic’ database to identify patients who had both 
USS and CT-scan for UUT evaluation between September 2015 and August 2017; and 
calculated the diagnostic accuracy of these imaging modalities for histologically confirmed 
UUT cancers. Furthermore, we identified risk factors in our diagnostic algorithm for 
haematuria and conducted regression analysis to determine their ability to predict UUT 
malignancies. 
Results: Overall, 575 patient records were studied. Age range was 21 – 92 years, M:F was 
1.4:1, majority (81.2%) had visible haematuria and 12 (2.1%) UUT cancers were diagnosed 
[Renal cell carcinoma- 1.4%; Upper tract urothelial cancer 0.7%]. USS and CT-scan had 
diagnostic accuracy for UUT cancers of 95.8% and 99.1% respectively (p<0.001). Haematuria 
type was a significant consideration only on univariate analysis while multivariate binary 
logistic regression showed that male gender, smoking, occupational exposure and positive 
urologic history were the main risk-factors associated with UUT malignancies.  
Conclusion: USS and CT-scan have comparably high diagnostic accuracy for detecting UUT 





utilized in a risk-based diagnostic algorithm. Larger, multicentred studies are needed to 
validate our findings and influence guideline development. 
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Haematuria is common, and may account for up to 10% of referrals to a urology service [1],[2]. 
Though it is generally accepted that cystoscopy is gold-standard for lower urinary tract 
evaluation following presentation with haematuria, the choice of diagnostic modality for the 
upper urinary tract (UUT) remains difficult and somewhat controversial [3]. This is because 
rationale for UUT imaging is multifactorial and depends on clinical presentation, renal 
function, pregnancy status, availability of resources, cost implication and local policy [2]. 
There is no consensus across urologic guidelines on a diagnostic algorithm for UUT evaluation 
in patients with haematuria (Table 1). The American Urology Association (AUA) Guidelines 
(2012 - 2019) recommend contrast-enhanced computerized tomography scan (CT-scan) for 
all patients above 35 years, with caveat for clinicians to individualize management when 
necessary based on patient's history and context of available resources [4]. Guidelines across 
Europe, Asia and other parts of the world on the other hand are either silent, or recommend 
a stratified approach with renal ultrasound (USS) as initial investigative modality for the UUT 
[2],[5],[6],[7].  
USS therefore remains popular among General practitioners (GPs), Nephrologists and 
Urologists in most parts of the globe and is attractive because it is relatively cheap, readily 
available (including in the office), has no adverse effects on renal function, does not involve 
radiation exposure and has good ability to assess the renal parenchyma for masses and also 
exclude hydronephrosis [2],[8],[9],[10]. In addition, USS is helpful for evaluating hyper-
attenuating renal lesions detected on CT-scan in order to distinguish benign hyperdense cysts 





USS evaluations are carried out yearly on a global scale. For instance, a National Health Service 
(NHS) dataset revealed about 462,585 renal and bladder USS examinations were carried out 
in England during the 2016-2018 period [12]. Recent data from the United States and Canada 
equally suggest a similar high usage of USS in the North American sub-region [13]. Such 
significant utilization of USS examinations therefore justifies a need for validation studies to 
assess the diagnostic performance of this imaging modality in order to determine its 
continued relevance in the real-world.  
Generally, it is believed that imaging with CT-scan is best for UUT evaluation following 
presentation with haematuria [14],[15]. However, large studies have confirmed that UUT 
cancers are rare, with prevalence only between 2.14 and 2.60% [3],[16]. Most scans will 
therefore be unsurprisingly negative and research has suggested that up to 1,018 CT-scan 
evaluations may be necessary to diagnose an additional UUT malignancy [17]. To the best of 
our knowledge, there are no risk prediction models for UUT cancers in patients with 
haematuria. We however believe it is important to explore ways of improving patient 
selection for UUT imaging so as to avoid exposing patients unduly to potential hazards 
including radiation-induced secondary malignancies, contrast nephropathy and anaphylactic 
contrast reaction [14],[18]. 
The aim of this study was therefore to evaluate the accuracy of USS compared to CT-scan for 
UUT malignancies and also determine the important considerations that could be used to 
predict UUT cancers in a risk-based diagnostic algorithm for haematuria. 
 






Participants and Imaging modalities 
The database of all patients evaluated for visible or non-visible haematuria in our university 
hospital between September 2015 and August 2017 was reviewed after obtaining approval 
from our clinical audit and effectiveness department. Patients were referred to our urology 
service by GPs, emergency physicians and consultants in other specialties if they met 
diagnostic criteria for haematuria spelt out in the guidelines of the National Institute for 
Health and Care Excellence (NICE)- Figure 1 [19]. Visible haematuria was self-reported by 
patients to the referring physician, while non-visible haematuria was defined as ≥1+ red blood 
cells on urine dipstick on at least two occasions. 
Our diagnostic algorithm is summarized in Figure 1 and involves clinical evaluation, flexible 
cystoscopy for the lower tracts and USS for UUT assessment in all patients; usually on same 
day in a ‘haematuria clinic’ setting. Contrast enhanced CT-scan for further UUT evaluation was 
thereafter performed within a few days in patients categorized as high-risk for UUT 
malignancy. In our practice, these are patients with significant smoking history and other risk 
factors similar to those in the best practice policy of the AUA [20]; those with UUT 
abnormalities on USS and individuals with a positive urologic history. For the purpose of this 
study, urologic history was defined as any of loin pain, recurrent urinary tract infections, 
history of urinary tract stones or concomitant/prior history of urologic malignancy. 
The USS evaluations were carried out by highly skilled sonographers (with 12-25 years’ 





3.5 MHz curvilinear probe. Contrast or doppler interrogation were used if necessary, though 
not as routine. The acquired ultrasound images were stored so could be further reviewed in 
our multidisciplinary team (MDT) meetings if required. 
Our local CT-scan protocol for haematuria involves an initial unenhanced scan, followed by a 
contrast scan using split bolus technique in order to combine nephrogenic and excretory 
phases in a single acquisition; thereby minimizing radiation exposure. The patients were 
asked to drink about 1.5L of water over the two hours prior to their appointment. We inject 
30-35 mls of Omni 300 into a vein on the upper limb, wait 12 minutes and then inject an 
additional 50mls at 1.5mls per second using a pressure injector. There is a 75 sec delay before 
the scanner starts to achieve a portal venous phase. We utilize either the ‘Toshiba Aquillion 
One’ (320 slice) or the ‘Toshiba Aquillion 64’ (64 slice) for the CT-scans and they were are all 
carried out with the patient in the supine position.  
Suspected UUT malignancies on imaging were reviewed by uro-radiologists in our MDT 
meetings and histologic confirmation and subsequent management such as renal biopsy, 
diagnostic ureteroscopy, nephrectomy or nephroureterectomy was thereafter carried out as 
appropriate.  
De-identified records of patients who had both USS and CT-scan were extracted from our 
electronic database and demographic characteristics, identifiable risk factors, USS/CT-scan 







This was conducted using the Statistical Package for Social Sciences version 21.0 (IBM Corp., 
Armonk, New York, USA). Statistical significance was set at p < 0.05 and 95% confidence 
interval. Means and standard deviations were calculated for continuous variables. The 
relationship between risk factors and histologically confirmed UUT malignancy was evaluated 
using univariate and multivariate analysis. Univariate association was determined using 
independent sample t-test for parametric continuous variables and cross-tabulation utilizing 
likelihood ratio or Pearson’s Chi-square for categorical variables. Multivariate binary logistic 
regression was carried out to determine significant associations between risk factors and 
confirmed UUT cancers. Furthermore, the likelihood ratio, sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of USS and 
CT-scan for UUT malignancies were determined. The STARD checklist [21] was completed 
since this was a diagnostic accuracy study (Online Resource 1). 
 
RESULTS 
There were 580 patients who had both USS and CT-Scan for UUT evaluation during the study 
period and their outcomes are summarized in Figure 2. Five individuals with suspicious 
imaging findings but no histologic confirmation of malignancy were excluded, leaving data of 
575/580 (99.1%) patients for analysis.  
The age range of studied patients was 21 – 92 years, male to female ratio was 1.4:1 and 
majority (81.2%) had visible haematuria. We diagnosed 12/575 (2.1%) UUT cancers, with male 
preponderance of cases (11/12; 91.7%). They all had visible haematuria (12/12; 100%) and no 





showed that male gender, smoking (>20 pack year), occupational exposure and positive 
urologic history were the significant high-risk features associated with histologically 
confirmed UUT cancers (Table 2).  
A comparison of USS and CT-scan performance for detecting UUT malignancies is presented 
in Table 3. In summary, USS and CT-scan have accuracy of 95.8% and 99.1% respectively. All 
patients diagnosed with an UUT cancer had a suggestive abnormality on both USS and CT-
scan images (Online resource 2). 
 
DISCUSSION 
There are three principal outcomes from this study. First, we have presented our diagnostic 
algorithm for UUT evaluation following presentation with haematuria. Second, we found that 
the significant high-risk features associated with UUT cancers are male gender, smoking, 
occupational exposure and a prior or concomitant urologic history. Third, our data suggests 
that USS has comparable diagnostic accuracy to CT-scan for detecting UUT malignancies in 
patients with haematuria.  
The significant high-risk features for UUT cancers identified in our study are not surprising, 
but consistent with previous documentation in literature [20],[22]. Age was not recognized 
as a significant risk factor in this study and our sub-analysis did not identify a specific cut-off 
age for occurrence of UUT cancers. The UK NICE guideline for haematuria was last updated in 
2015 and age threshold of 45-years was introduced at the time on the premise that PPV of 





couple of patients (15, 2.6%) below 45-years recruited into our study around time of 
transition to current updated NICE guideline. Our youngest patient with UUT cancer was only 
33-years old, younger than the threshold for evaluation of haematuria recommended in the 
AUA or NICE guidelines; and a pointer towards difficulty associated with basing threshold for 
patient evaluation on a fixed age alone.  
Though the haematuria type (visible vs non-visible) was a significant univariate predictor for 
UUT cancers; this association surprisingly disappeared on multivariate analysis and we 
speculate that this is because haematuria type is less specific than other identified risk factors 
as a pointer toward UUT malignancies. There are many possible benign urologic or systemic 
aetiologies for haematuria, and it is also possible that visible haematuria is a progression of 
non-visible haematuria in patients with UUT cancers. It is however important to highlight that 
no UUT mitotic lesion was diagnosed following presentation with non-visible haematuria in 
this study; supporting previous publications demonstrating that UUT malignancies are a rare 
occurrence in non-visible haematuria [3],[23].  
Our study showed that USS and CT-scan both have significantly high accuracy for UUT 
malignancies. Since all patients diagnosed with an UUT cancer had abnormalities on their USS 
and CT-scan, both imaging modalities therefore had a NPV of 100% which could give some 
reassurance following negative UUT evaluation in patients with haematuria. CT-scan correctly 
identified all patients with RCC; but five patients with suspected UTUC were re-classified as 
normal following ureteroscopy, giving CT-scan a positive predictive value (PPV) of 70.6%. This 
PPV of CT-scan is better than values previously reported in literature. Cauberg et al [14] found 





selection using our risk-based individualized algorithm. We believe our approach was able to 
prevent many unnecessary and potentially harmful invasive diagnostic procedures that would 
have been associated with a lower PPV of CT-scan. USS on the other hand was less specific, 
with PPV of only 33.3%. Abnormalities on USS is trigger for further diagnostic imaging, so the 
low PPV of USS probably increased the yield from our CT-scan evaluations. We excluded 5 
(0.9%) patients without histology but considering they also all had findings suggestive of UUT 
cancer on their USS images means our outcomes would not have been significantly different 
if they were included in our analysis. 
Considering that about 98% of CT-scans in our study were negative and no new UUT 
malignancy was detected following a completely normal renal USS evaluation raises the 
possibility that carrying out CT-scan may have been an ‘over-investigation’ for some patients. 
We therefore argue that choice of UUT imaging modality be individualized based on patients’ 
risk-assessment. Though there is a possibility that USS may miss very small RCC (below 3cm) 
or early UTUC that is not causing fullness or dilatation of the collecting system, our data 
suggests that such patients are likely to be in the high-risk category of our algorithm and 
would still require further imaging with CT-scan following a supposedly normal USS 
examination.  
We postulate that a practicable risk-based algorithm for UUT evaluation like ours would 
improve selection of patients who would benefit maximally from CT-scan evaluation while 
limiting undue risks from radiation or contrast exposure. Our study supports the use of USS 
for first-line UUT imaging in patients with haematuria and we believe it may potentially be 





potential modification of our algorithm would involve offering patients classified as high-risk 
an upfront CT-scan without prior renal USS evaluation. In our practice, this was not the case 
because the initial USS evaluation was done in an ‘Haematuria clinic’ setting so didn’t pose 
any additional logistical challenges and we have found the ancillary information such as post-
void residual volume measurement derived from the USS evaluation useful for holistic 
evaluation of our patients.  
Some limitations of our study must be recognized. The research was conducted in a single 
institution so our experience may not necessarily be generalizable to other environments or 
sub-populations considering there may be differences associated with USS operator 
experience, UUT cancer incidence and risk factor profile in patients across different 
geographical locations. Second, the USS results were known by Radiologists while reporting 
the CT-scan images and may have led to some bias and reduction in false negative rates of 
CT-Scan in our study.  Furthermore, patients with normal CT-scan did not routinely have 
additional UUT evaluation, and this may have impacted on our sensitivity and diagnostic 
accuracy calculations. Lastly, the final outcomes of patients who had only USS for UUT 
evaluation was not reported as beyond the scope of this study. We have however previously 









UUT malignancies are uncommon and in order to minimize risks associated with aggressive 
patient evaluation following presentation with haematuria, we recommend that choice of 
UUT imaging modality should be individualized using a risk-based algorithm. Based on our 
data, USS and CT-scan both have comparably high accuracy for UUT malignancies so USS 
should remain first-line UUT investigation of choice and may be considered as an adequate 
modality in selected low-risk patients. High-risk considerations identified in our study are 
male gender, smoking, occupational exposure and a prior or concomitant urologic history and 
clinicians should have a low threshold to offer CT-scan imaging in this cohort. Larger, 
multicentred studies across different populations are needed to validate our findings and 
guide future guideline development. 
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Fig. 1: Diagnostic algorithm for Haematuria 
Fig. 2: Flow diagram of results 
 
Online resource 1: STARD checklist 
Online resource 2: Breakdown of upper urinary tract cancers diagnosed 
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Table 1. Summary of guideline recommendations for first line upper urinary tract imaging 
for haematuria evaluation 
 
Organisation First line UUT imaging 
AUA[4]  CTU for all patients aged > 35yrs regardless of haematuria type 
ACP [26] No specific guidance 
BAUS [27] No specific guidance 
Canadian working 
group [28] 
Asymptomatic microscopic haematuria: physician preference 
Symptomatic microscopic haematuria and Gross haematuria: CTU 
Dutch guidelines [7] Low risk (NVH <50yrs): USS 
Medium risk (NVH > 50yrs & VH < 50yrs): USS 
High risk (VH > 50yrs or risk score >6 ): CTU 
EAU [29] Use renal and bladder USS and/or computed tomography-intravenous 
urography (CT-IVU) during the initial work-up in patients with 
haematuria 
 
ESUR [30] NVH – USS 
Macroscopic haematuria with low & medium probability for urothelial 
cancer: USS 
Macroscopic haematuria, at high-risk for urothelial cancer: CTU 
Japanese guidelines [6] Low and medium risk: USS 
High risk: CTU 
NICE guidelines[19]  No specific guidance 
  
UUT - upper urinary tract; AUA – American Urologic Association; CTU – Computed 
Tomography Urogram, ACP – American College of Physicians; BAUS – British Association of 
Urologic Surgeons; USS – ultrasound; NVH – non-visible haematuria; VH – visible haematuria; 
EAU – European Association of Urology; ESUR – European Society of Urogenital Radiology; 






Table 2: Demographic characteristics and risk-factors for upper urinary tract malignancies 
 All Patients 











Value p-value Beta p-value 














31-40 7 (1.2%) 1 (0.2%) 6 (1.0%) -17.332 0.999 
41-50 74 (12.9%) 0 74 (12.9%) -35.769 0.995 
51-60 107 (18.6%) 2 (0.3%) 105 (18.3%) -12.552 0.998 
61-70 183 (31.8%) 6 (1.0%) 177 (30.8%) -26.341 0.996 
71-80 161 (28.0%) 3 (0.5%) 158 (27.5%) -23.142 0.996 
>80 35 (6.1%) 0 35 (6.1%) -20.880 0.997 
Gender Male 337 (58.6%) 11 (1.9%) 326 (56.7%) 6.749 0.009$ -3.085 0.009 
Female 238 (41.4%) 1 (0.2%) 237 (41.2%) 
Haematuria 
type 
Visible 467 (81.2%) 12 (2.1%) 455 (79.1%) 5.052 0.025$ -16.541 0.996 
Non-visible 108 (18.8%) 0 108 (18.8%) 
Smoking  
(>20 pack year) 
Yes 176 (30.6%) 10 (1.7%) 166 (28.9%) 14.663 <0.001$ -3.656 <0.001 







Yes 122 (21.2%) 2 (0.3%) 120 (20.9%) 0.161 0.689$ 4.549 0.012 
No 453 (78.8%) 10 (1.7%) 443 (77.0%) 
Urologic 
history++ 
Yes 104 (18.1%) 5 (0.9%) 99 (17.2%) 4.599 0.032** -5.094 0.001 
No 471 (81.9%) 7 (1.2%) 464 (80.7%) 
*Independent sample t-test; $Likelihood ratio; **Chi-square  























NICE: National Institute for Health and Care Excellence 
UUT: Upper urinary tract 




















aNICE Guidelines for evaluation 
- Aged ≥45yrs with unexplained visible haematuria without urinary tract infection or visible haematuria that persists or recurs after 
successful treatment of urinary tract infection 
- Aged ≥60yrs with unexplained non-visible haematuria and any of dysuria, raised serum white cell count or recurrent/persistent 
unexplained urinary tract infection 
 
*High risk features for UUT malignancy 
- Significant smoking history (pack year ≥20) 
- Occupational exposure to chemicals or dyes 
- Urologic history: loin pain, urinary tract infections, history of stones, concomitant or prior history of urologic malignancy 
- Recurrent visible haematuria 
- Single episode of visible haematuria or non-visible haematuria and positive urologic history 
- Upper urinary tract abnormality on Ultrasound - dilatation, mass, complex cyst etc 
 
** Low risk features for UUT malignancy 




























RCC = 8 (1.4%)







1. 90-year old male with left hydroureteronephrosis on USS and CT-scan. Ureteroscopy revealed a solid tumour in distal left 
ureter. Multidisciplinary team (MDT) recommended expectant management as not able to withstand major surgery 
2. 88-year old male with left hydronephrosis and probable mass around pelvi-ureteric junction on both USS and CT-scan. Unfit 
for intervention due to comorbidities 
3. 81-year male with right hydronephrosis and suspicious abnormality in renal pelvis on USS and CT-scan. Unfit, due to 
comorbidities 
4. 80-year old male with 3cm ill-defined solid, enhancing left renal mass detected on USS and confirmed with CT-scan. MDT 
recommended surveillance 
5. 70-year old male with 4.3cm solid enhancing left renal mass present on USS and CT-scan. Unable to have major surgery 
due to significant co-morbidities so MDT recommended surveillance 
 
